What the Evidence Says About Ozempic and Gastroparesis in Georgia

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Occupational Risk

If you or a loved one has been taking Ozempic and developed persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. The medical community has long recognized that medications can have unintended effects on digestive function, and recent reports have raised questions about this particular drug. This page summarizes the available evidence on Ozempic-associated gastroparesis to help you understand the potential risks.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a clinical condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, abdominal pain, and bloating. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to significant morbidity, including malnutrition, dehydration, and impaired quality of life. In the context of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes mellitus, gastrointestinal adverse reactions are well-documented. Clinical trial data indicate that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo, with nausea reported in 15.8% of patients on 0.5 mg and 20.3% on 1 mg, compared to 6.1% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Vomiting occurred in 5.0% and 9.2% of patients on 0.5 mg and 1 mg, respectively, versus 2.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These adverse reactions were most common during dose escalation, and discontinuation rates due to gastrointestinal issues were higher in Ozempic-treated patients (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors, which slow gastric emptying as part of their therapeutic effect on glucose regulation. This pharmacodynamic property can lead to delayed gastric emptying, potentially exacerbating or inducing gastroparesis in susceptible individuals. Postmarketing reports have highlighted risks of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, due to residual gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for significant gastric retention, a hallmark of gastroparesis. While the label does not explicitly list gastroparesis as a known adverse reaction, the documented gastrointestinal effects and mechanistic plausibility support a link between Ozempic use and the development or worsening of gastroparesis.

Statute of Limitations for Ozempic Claims in Georgia

For individuals in Georgia who developed gastroparesis after using Ozempic, settlement-related considerations depend on the statute of limitations, which governs the time frame within which a legal claim must be filed. In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical for patients who experienced symptoms of gastroparesis, such as persistent nausea, vomiting, or abdominal pain, after starting Ozempic. The clock typically starts when the patient becomes aware of the link between the drug and their condition, which may require medical diagnosis and confirmation. The timeline between exposure to Ozempic and documented harm is another key factor. Clinical trials show that gastrointestinal adverse reactions often occur during dose escalation, but the onset of gastroparesis may be delayed or progressive. Patients who used Ozempic for extended periods may have developed symptoms gradually, complicating the determination of when the injury was discovered. For settlement purposes, evidence of a causal relationship, such as temporal association and exclusion of other causes, is essential. Patients should document the start date of Ozempic use, the onset of gastroparesis symptoms, and any medical evaluations confirming the diagnosis. This documentation helps establish the timeline for statute of limitations purposes.

Risk Context and Legal Considerations

Risk anchors for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but does not specifically mention gastroparesis as a potential outcome. This may raise questions about whether patients and healthcare providers were adequately informed of the risk. In summary, patients in Georgia who developed gastroparesis after using Ozempic should be aware of the two-year statute of limitations from the date of discovery of the injury. The adequacy of warnings, mechanistic plausibility, and clinical trial data support a potential link between Ozempic and gastroparesis. Legal claims may consider whether the manufacturer provided sufficient warnings about the risk of delayed gastric emptying and gastroparesis. Affected individuals should consult with a legal professional to assess their specific circumstances and ensure timely filing of any claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Georgia?

In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This means affected individuals must file their claim within two years of becoming aware of the link between Ozempic and their gastroparesis.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its therapeutic effect. This pharmacodynamic property can lead to delayed gastric emptying, potentially exacerbating or inducing gastroparesis in susceptible individuals. Clinical trials have shown higher rates of nausea, vomiting, and other gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.